Evidence map›Paper›PMID 39928908›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2025

Progressive Myelitis in a 63-Year-Old Woman: A Case Report From the National Multiple Sclerosis Society Case Conference Proceedings.

Kimberly A DiMauro, Morgan E Heber, Jonathan Lee, Jeffrey A Cohen, Eoin P Flanagan, Claire Riley, Myla D Goldman, Scott S Zamvil, Amy C Kunchok

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Clinical characteristics, management and outcomes in immune checkpoint inhibitor-induced central nervous system demyelinating disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kimberly A DiMauroMellen Center for Multiple Sclerosis Treatment and Research, Neurologic Institute, Cleveland Clinic Foundation, OH.ORCID 0009-0009-1827-1937
Morgan E HeberDepartment of Neurology, Neurologic Institute, Cleveland Clinic Foundation, OH.
Jonathan LeeDiagnostics Institute, Cleveland Clinic Foundation, OH.ORCID 0000-0002-5955-5145
Jeffrey A CohenMellen Center for Multiple Sclerosis Treatment and Research, Neurologic Institute, Cleveland Clinic Foundation, OH.ORCID 0000-0001-9245-9772
Eoin P FlanaganDivision of Multiple Sclerosis and Autoimmune Neurology, Department of Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-6661-2910
Claire RileyMultiple Sclerosis Center, Department of Neurology, Columbia University Irving Medical Center, New York.ORCID 0000-0002-2133-9607
Myla D GoldmanDepartment of Neurology, Virginia Commonwealth University, Richmond; and.ORCID 0000-0002-5675-945X
Scott S ZamvilDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco.ORCID 0000-0003-2720-9915
Amy C KunchokMellen Center for Multiple Sclerosis Treatment and Research, Neurologic Institute, Cleveland Clinic Foundation, OH.ORCID 0000-0002-8387-6491

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a case of myelitis in a 63-year-old woman with breast adenocarcinoma treated with pembrolizumab. MRI showed multiple T2-hyperintense lesions throughout the spinal cord, and CSF demonstrated lymphocytic pleocytosis. We discuss the differential diagnosis of myelitis in the setting of cancer and immune checkpoint inhibitors.

Indexed as

AdenocarcinomaAntibodies, Monoclonal, HumanizedBreast NeoplasmsImmune Checkpoint InhibitorsMyelitisDiagnosis, DifferentialDisease ProgressionFemaleHumansMagnetic Resonance ImagingMiddle AgedAntibodies, Monoclonal, HumanizedImmune Checkpoint Inhibitorspembrolizumab

Identifiers

PMID39928908
PMCPMC11813231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.